Summit Therapeutics Flags Going Concern Risk Over Cash Needs
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
The Era of the One-Size-Fits-All Cancer Drug Is Ending
What's Going On With Summit Therapeutics Stock On Monday?
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
Summit Therapeutics Stock Dips After Q1 Financial Report
IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst